An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs. The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection. Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab.

Treatment of T cells with monoclonal anti-CD3 antibodies and anti-CD28 antibodies provide a co-stimulatory signal that engages the TCR which can be used for antigen-induced activation. Using functional antibodies, as described below, with or without growth factors is a more economical method to expand T cell populations.

2019年6月9日 · We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor–nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1...

Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses.

Antibodies that detect CD3 can be used in several scientific applications, including Flow Cytometry, Immunohistochemistry, Western Blot, Immunocytochemistry and Immunoprecipitation. These antibodies target CD3 in Human, Mouse, Rat, …

The CD3 protein complex was first identified by immunoprecipitation experiments using human T cells. The determination of glycosylation state of the individual CD3 ε, CD3 γ and CD3 δ polypeptide chains was subsequently determined using endoglycosaminidases and specific anti-CD3 antibodies.

These findings suggest that nasal anti-CD3 represents a promising new therapeutic approach for treating TBI and potentially other forms of acute brain injury.

2021年6月17日 · Orthoclone OKT3 targets the CD3 molecule that is present exclusively on T cells and depletes them from the circulation, which makes the drug an effective immunomodulator.

2007年7月20日 · At variance with presently available therapies for autoimmunity and transplantation, CD3-specific monoclonal antibodies afford long-term effects following a short administration — a...

Our results suggest that anti-CD3 mAbs were a potential therapy for improving AUC of C-peptide and insulin use in type 1 diabetes.

Anti-CD3 monoclonal antibody (mAb) is a potent, clinically applied immunosuppressant [83], which has been verified to enhance the differentiation of Tregs via the actions of TGF-β [84]. By administering anti-CD3 mAb, Winer and colleagues achieved a long-term restoration on insulin resistance and glucose tolerance in DIO mice [ 63 ].

Monoclonal anti-CD3 antibodies (mAbs) have been used clinically for two decades to reverse steroid-resistant acute graft rejection. In autoimmune diabetes, short course treatment with FcR non-binding (FNB) anti-CD3 mAb in mice with recent onset …

Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.

Anti-CD3 antibodies act as potent immunosuppressive agents by modulating the CD3/T-cell receptor (TCR) complex. They have been used in patients to prevent short term allograft rejection and were also shown to induce long-term remission of autoimmune diabetes in nonobese diabetic (NOD) mice [8].

2019年8月15日 · Methods: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease.

2009年11月2日 · Recently, orally administered anti-CD3 monoclonal antibody has been shown as an inducer of novel regulatory T cells expressing latency-associated peptide (LAP) on their surface, which potently prevents systemic autoimmunity. In the present study, we hypothesized that oral anti-CD3 antibody treatment may inhibit atherosclerosis in mice.

2025年3月15日 · Explore the mechanisms of CD3 antibodies, their interaction with T-cells, and the evolving distinctions that shape their clinical and research applications. CD3 antibodies have emerged as a key tool in immunotherapy, particularly for their role in modulating T-cell activity.

2022年11月22日 · Anti-CD3 mAbs are promising disease-modifying treatments for T1D. Their role in T1D may introduce short-term and long-term benefits with the potential to mitigate the significant disease burden; however, more evidence is required for an accurate assessment.

An Anti-CD3 Monoclonal Antibody is a type of antibody that targets CD3 receptors on T-cells, used in the treatment of autoimmune diseases by modulating the immune response. AI generated definition based on: Side Effects of Drugs Annual, 2012

The anti-CD3 used was directed against the invariant CD3ε chain and was unable to bind Fc receptors. The antibody given intraperitoneally for 6 or 10 days after disease induction was able to suppress EAU development in both treatment schemes, indicating its effectiveness during disease onset and upon priming of T cells.